Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 6, 2011, Pages 1316-1325

  Marz W ^a,b,c   Genser, Bernd ^c,d   Drechsler, Christiane ^e   Krane, Vera ^e   Grammer, Tanja B ^c   Ritz, Eberhard ^f   Stojakovic, Tatjana ^b   Scharnagl, Hubert ^b   Winkler, Karl ^g   Holme, Ingar ^h   Holdaas, Hallvard ⁱ   Wanner, Christoph ^f  

^a SYNLAB ACADEMY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d BGStats Consulting   (Austria)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; HEART DEATH; HEART INFARCTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SUDDEN DEATH; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; GERMANY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958244625     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09121010     Document Type: Article

References (50)

1. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108: 2154-2169, 2003
3. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41: 11-17, 2003
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278, 2005
5. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: A meta-analysis. Lancet 371: 117-125, 2008
6. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu D, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
7. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5: 2929-2936, 2005
8. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138: 98-104, 2003
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial. Lancet 361: 2005-2016, 2003
10. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
11. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J:Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 49: 373-382, 2007
12. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M: Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss:A post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 55: 42-49, 2010
13. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 83: 870-879, 2008
14. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
15. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen- Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
16. Genser B, März W: Low density lipoprotein cholesterol, statins and cardiovascular events: A meta-analysis. Clin Res Cardiol 95: 393-404, 2006
17. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D: The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Ther 31: 236-244, 2009
18. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 326: 1423, 2003
19. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453-1460, 1998
20. Simes R, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A: LIPID Study Investigators: Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105: 1162-1169, 2002
21. Wanner C, Krane V, Ruf G, März W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222-S226, 1999
22. Wanner C, Krane V, März W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259-266, 2004
23. Andersen PK, Gill RD: Cox_s regression model for counting processes: A large sample study. Ann Stat 10: 1100-1120, 1982
24. Kelly PJ, Lim LL: Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med 19: 13-33, 2000
25. Hernandez AV, Eijkemans MJ, Steyerberg EW: Randomized controlled trials with time-to-event outcomes: How much does prespecified covariate adjustment increase power? Ann Epidemiol 16: 41-48, 2006
26. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829-1839, 2007
27. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990
28. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9: S24-S30, 1998
29. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61: 1887-1893, 2002
30. Chiang CK, Ho TI, Hsu SP, Peng YS, Pai MF, Yang SY, Hung KY, Tsai TJ: Low-density lipoprotein cholesterol: Association with mortality and hospitalization in hemodialysis patients.Blood Purif 23: 134-140, 2005
31. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18: 304-311, 2007
32. Vaziri ND: Causes of dysreguation of lipid metabolism in chronic renal failure. Semin Dial 22: 644-651, 2009
33. Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006
34. Mehta S, Farmer JA: Obesity and inflammation: A new look at an old problem. Curr Atheroscler Rep 9: 134-138, 2007
35. Ridker P, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844, 1998
36. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965, 2001
37. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, Mc- Cabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28, 2005
38. Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactiveprotein: A meta-analysis. J Am Coll Cardiol 49: 2003-2009, 2007
39. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235, 1999
40. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
41. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001
42. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An 1324 Clinical Journal of the American Society of Nephrology individual participant meta-analysis. Lancet 375: 132-140, 2010
43. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, König W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008
44. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335: 1001-1009, 1996
45. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504, 2004
46. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360: 1623-1630, 2002
47. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002
48. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl: S207-S210, 2003
49. Sharp Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 160: 785-794, 2010
50. Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmolzer I, Wascher TC, März W: Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest 40: 187-194, 2010